Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

NicVAX/Placebo as an Aid for Smoking Cessation

ClinicalTrials.gov ID: NCT00836199

Public ClinicalTrials.gov record NCT00836199. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.

Study identification

NCT ID
NCT00836199
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Nabi Biopharmaceuticals
Industry
Enrollment
1,000 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 2009 (Type not available)
Primary completion
Jul 2011 (Actual)
Completion
Jul 2011 (Actual)
Last update posted
May 9, 2012

2009 – 2011

United States locations

U.S. sites
22
U.S. states
18
U.S. cities
22
Facility City State ZIP Site status
NicVAX Investigator Tucson Arizona — —
NicVAX Investigator Los Angeles California — —
NicVAX Investigator Newport Beach California — —
NicVAX Investigator San Diego California — —
NicVAX Investigator Denver Colorado — —
NicVAX Investigator Farmington Connecticut — —
NicVAX Investigator Miami Florida — —
NicVAX Investigator St. Petersburg Florida — —
NicVAX Investigator Boise Idaho — —
NicVAX Investigator Lexington Kentucky — —
NicVAX Investigator Baltimore Maryland — —
NicVAX Investigator College Park Maryland — —
NicVAX Investigator Boston Massachusetts — —
NicVAX Investigator Minneapolis Minnesota — —
NicVAX Investigator Omaha Nebraska — —
NicVAX Investigator Rochester New York — —
NicVAX Investigator Raleigh North Carolina — —
NicVAX Investigator Portland Oregon — —
NicVAX Investigator Draper Utah — —
NicVAX Investigator Norfolk Virginia — —
NicVAX Investigator Seattle Washington — —
NicVAX Investigator Madison Wisconsin — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00836199, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 9, 2012 · Synced Oct 28, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00836199 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →